Patents by Inventor Smita Nair
Smita Nair has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240117310Abstract: The present disclosure describes systems and methods for in vitro differentiation of human cross-presenting CD141+CLEC9A+ dendritic cells from mobilized peripheral blood CD34+ hematopoietic stem cells. The dendritic cells may further comprise an antigen or nucleic acid encoding an antigen. Methods of using the cells are also provided.Type: ApplicationFiled: September 15, 2023Publication date: April 11, 2024Inventors: Smita NAIR, Adam SWARTZ
-
Patent number: 11428691Abstract: Methods of testing tumor samples for mutational burden and/or for expression profiles permit the prediction of responsiveness of an individual to immunotherapy comprising PVSRIPO. Those predicted to respond are treated with PVSRIPO and those predicted not to respond are treated with other agents.Type: GrantFiled: January 23, 2019Date of Patent: August 30, 2022Assignee: Duke UniversityInventors: David Ashley, Darell Bigner, Matthias Gromeier, Smita Nair
-
Patent number: 11331343Abstract: Chimeric poliovirus is capable of activating antigen presenting cells. The activation of the antigen presenting cells may be in vitro, ex vivo, or in vivo. The activated antigen presenting cells may be administered alone or with an antigen or vaccine. The activated antigen may be loaded in vitro or ex vivo with antigen to form antigen-loaded, activated, antigen presenting cells. These may be administered therapeutically. Therapeutic administration of antigen presenting cells may be used as an adjuvant to other therapies.Type: GrantFiled: June 29, 2017Date of Patent: May 17, 2022Assignee: Duke UniversityInventors: Smita Nair, Michael Brown, Darell Bigner, Matthias Gromeier
-
Publication number: 20210338811Abstract: Regional, tumor-targeted, cytotoxic therapy, such as D2C7-immunotoxin (D2C7-IT), not only specifically target and destroy tumor cells, but in the process initiate immune events that promote an in situ vaccine effect. The antitumor effects are amplified by immune checkpoint blockade which engenders a long-term systemic immune response that effectively eliminates all tumor cells.Type: ApplicationFiled: July 15, 2021Publication date: November 4, 2021Inventors: Darell Bigner, Vidyalakshmi Chandramohan, Smita Nair, Matthias Gromeier, Xuhui Bao, Ira H. Pastan
-
Patent number: 11065332Abstract: Regional, tumor-targeted, cytotoxic therapy, such as D2C7-immunotoxin (D2C7-IT), not only specifically target and destroy tumor cells, but in the process initiate immune events that promote an in situ vaccine effect. The antitumor effects are amplified by immune checkpoint blockade which engenders a long-term systemic immune response that effectively eliminates all tumor cells.Type: GrantFiled: November 4, 2016Date of Patent: July 20, 2021Assignees: Duke University, The Government of The United States as Represented by the Secretary of Health and Human Services, National Institutes of HealthInventors: Darell Bigner, Vidyalakshmi Chandramohan, Smita Nair, Matthias Gromeier, Xuhui Bao, Ira H. Pastan
-
Publication number: 20210214442Abstract: Provided is a method of treating a tumor in an individual by neoadjuvant therapy, wherein the individual has not previously undergone a resection of the tumor, the method comprising administering an immunotoxin alone or an immune checkpoint inhibitor and an immunotoxin, such as D2C7-immunotoxin (D2C7-IT), followed by resection of the tumor. The method may further comprise administration of immune checkpoint inhibitor following resection.Type: ApplicationFiled: May 16, 2019Publication date: July 15, 2021Applicant: DUKE UNIVERSITYInventors: Darell BIGNER, Smita NAIR, Vidyalakshmi CHANDRAMOHAN
-
Publication number: 20210106633Abstract: Provided is a method of treating a tumor in an individual by neoadjuvant therapy, wherein the individual has not previously undergone treatment to effectively reduce tumor burden, the method comprising administering an oncolytic chimeric poliovirus construct, or an oncolytic chimeric poliovirus construct and an immune checkpoint inhibitor, followed by reduction of the tumor. The method may further comprise administration of immune checkpoint inhibitor or oncolytic chimeric poliovirus construct following reduction of tumor. Kits for performing the methods are also provided.Type: ApplicationFiled: April 2, 2019Publication date: April 15, 2021Applicant: Duke UniversityInventors: Darell Bigner, Matthias Gromeier, Smita Nair, Henry Friedman, Annick Desjardins
-
Publication number: 20210063398Abstract: Methods of testing tumor samples for mutational burden and/or for expression profiles permit the prediction of responsiveness of an individual to immunotherapy comprising PVSRIPO. Those predicted to respond are treated with PVSRIPO and those predicted not to respond are treated with other agents.Type: ApplicationFiled: January 23, 2019Publication date: March 4, 2021Applicant: Duke UniversityInventors: David Ashley, Darell Bigner, Matthias Gromeier, Smita Nair
-
Publication number: 20200368300Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. Combination with immune checkpoint inhibitors increases the anti-tumor effect. Tumors of different types are susceptible to the combination treatment, including but not limited to melanoma, glioglastoma, renal cell carcinoma, prostate cancer, breast cancer, lung cancer, medulloblastoma, and colorectal cancer.Type: ApplicationFiled: August 11, 2020Publication date: November 26, 2020Applicant: Duke UniversityInventors: Darell D. Bigner, Matthias Gromeier, Smita Nair, Vidyalakshmi Chandramohan
-
Patent number: 10744170Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. Combination with immune checkpoint inhibitors increases the anti-tumor effect. Tumors of different types are susceptible to the combination treatment, including but not limited to melanoma, glioglastoma, renal cell carcinoma, prostate cancer, breast cancer, lung cancer, medulloblastoma, and colorectal cancer.Type: GrantFiled: October 14, 2016Date of Patent: August 18, 2020Assignee: Duke UniversityInventors: Darell D. Bigner, Matthias Gromeier, Smita Nair, Vidyalakshmi Chandramohan
-
Publication number: 20190167718Abstract: Chimeric poliovirus is capable of activating antigen presenting cells. The activation of the antigen presenting cells may be in vitro, ex vivo, or in vivo. The activated antigen presenting cells may be administered alone or with an antigen or vaccine. The activated antigen may be loaded in vitro or ex vivo with antigen to form antigen-loaded, activated, antigen presenting cells. These may be administered therapeutically. Therapeutic administration of antigen presenting cells may be used as an adjuvant to other therapies.Type: ApplicationFiled: June 29, 2017Publication date: June 6, 2019Inventors: Smita Nair, Michael Brown, Darell Bigner, Matthias Gromeier
-
Publication number: 20180311346Abstract: Regional, tumor-targeted, cytotoxic therapy, such as D2C7-immunotoxin (D2C7-IT), not only specifically target and destroy tumor cells, but in the process initiate immune events that promote an in situ vaccine effect. The antitumor effects are amplified by immune checkpoint blockade which engenders a long-term systemic immune response that effectively eliminates all tumor cells.Type: ApplicationFiled: November 4, 2016Publication date: November 1, 2018Applicants: Duke University, THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN, SERVICES, NATIONAL INSTITUTES OF HEALTHInventors: Darell Bigner, Vidyalakshmi Chandramohan, Smita Nair, Matthias Gromeier, Xuhui Bao, Ira H. Pastan
-
Publication number: 20180296614Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. Combination with immune checkpoint inhibitors increases the anti-tumor effect. Tumors of different types are susceptible to the combination treatment, including but not limited to melanoma, glioglastoma, renal cell carcinoma, prostate cancer, breast cancer, lung cancer, medulloblastoma, and colorectal cancer.Type: ApplicationFiled: October 14, 2016Publication date: October 18, 2018Applicant: Duke UniversityInventors: Darell D. Bigner, Matthias Gromeier, Smita Nair, Vidyalakshmi Chandramohan
-
Patent number: 7785583Abstract: A method for eliciting an immune response to an antigen in a subject via (a) loading isolated antigen presenting cells with an antigen ex vivo; and (b) administering the antigen presenting cells to a subject at a pre-treated site.Type: GrantFiled: December 10, 2003Date of Patent: August 31, 2010Assignees: Argos Therapeutics, Inc., Duke UniversityInventors: Eli Gilboa, Smita Nair
-
Publication number: 20060121003Abstract: A method for eliciting an immune response to an antigen in a subject via (a) loading isolated antigen presenting cells with an antigen ex vivo; and (b) administering the antigen presenting cells to a subject at a pre-treated site.Type: ApplicationFiled: December 10, 2003Publication date: June 8, 2006Inventors: Eli Gilboa, Smita Nair
-
Publication number: 20060057130Abstract: Disclosed are cells and methods for treating or preventing tumor formation or infections with pathogens in a patient. The cells of the invention are antigen-presenting cells (e.g., dendritic cells or macrophage) that have been loaded with RNA derived from tumors or pathogens. By administering the RNA-loaded antigen-presenting cells to a patient, tumor formation or pathogen infections can be treated or prevented. Alternatively, the RNA-loaded cells can be used as stimulator cells in the ex vivo expansion of CTL. Such CTL can then be used in a variation of conventional adoptive immunotherapy techniques.Type: ApplicationFiled: October 17, 2005Publication date: March 16, 2006Applicant: DUKE UNIVERSITYInventors: Smita Nair, David Boczkowski, Eli Gilboa
-
Publication number: 20040115174Abstract: The present invention relates, in general, to cancer therapy and, in particular, to a method of treating cancer that involves immunization against an endothelial-specific product preferentially expressed during tumor angiogenesis or against a factor that contributes to the angiogenic process.Type: ApplicationFiled: July 3, 2003Publication date: June 17, 2004Applicant: Duke UniversityInventors: Eli Gilboa, Smita Nair, David Boczkowski